Rucaparib
Maintenance Rucaparib After Chemo Extends PFS in Some Metastatic Urothelial Cancers
Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib following platinum-based ...
APRIL 18, 2022
Rubraca Gains Approval for Use in BRCA-Mutated mCRPC
The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) for patients with deleterious BRCA ...
MAY 19, 2020
FDA Grants New Indication for Rubraca
The FDA granted a new indication for Rubraca for the maintenance treatment of recurrent ovarian, fallopian tube or ...
APRIL 6, 2018
Rubraca and Companion Diagnostic Approved for Advanced Ovarian Cancer
The therapy was approved for women with advanced ovarian cancer who have been treated with two or more ...
DECEMBER 18, 2016
Rucaparib Receives Priority Review for Advanced Mutant BRCA Ovarian Cancer
The therapy is being developed as monotherapy treatment of advanced ovarian cancer in patients with deleterious ...
AUGUST 24, 2016
